Actionable Tissue Intelligence
for Drug Development
Nucleai helps biopharma answer two critical questions: why does a therapy work, and which patients will benefit?
Our AI-driven platform combines multimodal tissue analysis with clinical outcomes linkage and traceable outputs, turning complex tissue biology into actionable intelligence for drug development decisions.
Partnership
What Tissue Intelligence Means
Tissue intelligence brings together multimodal image analysis, clinical outcomes linkage, and traceable outputs. Delivered as expert-led analysis, utilizing Quality by Design, with an established track record across pharma programs.
The result is structured, validated evidence that translational and biomarker teams can use to support, not another expression score to interpret.
Multimodal by design
Integrate H&E, IHC, multiplex imaging, and spatial transcriptomics.
AI-powered tissue analysis
Advanced models extract image features in greater depth to reveal spatial context.
Linked to clinical outcomes
Establish which features explain response, resistance, survival.
Traceable & explainable
Trace every finding back to the original image it came from.
Who We Work with
We work with biopharma sponsors wherever tissue biology is central to a program decision, across oncology, immunology, metabolic disease and beyond, and including drug modalities such as ADCs and multispecifics.
Our work supports translational medicine, clinical biomarker, and translational pathology teams. Additionally we collaborate with translational researchers and spatial biology platforms to turn spatial biology data into actionable and scalable insights.
Trusted by Leading Biopharma and Translational Researchers
Our partnership with Nucleai will help us accelerate the translation of spatial biology insights into clinical practice, ultimately improving patient care.
Nigel Jamieson, Professor of Hepatobiliary and Pancreatic Surgery
University of Glasgow
Nucleai’s technology stands out by being the first spatial AI tool used by pathologists for clinical trial patient selection that is directly connected to a drug development program.
Noga Yerushalmi, PhD, Investment Director
M Ventures (Corporate Strategic Venture Arm of Merck KGaA, Darmstadt, Germany)
of the Top 20 biopharma
12
+
clinical trials
30
+
indications
10
+
Data and Institutional Partners
Investors
Join Us in
Transforming Patient Care
At Nucleai, we bring together leading minds in pathology, medicine, biology, engineering, and artificial intelligence to tackle the most complex challenges in healthcare, with the goal of transforming patient care. Come join our team to revolutionize precision medicine.
Nucleai is certified to the highest international stands for information security and quality management.
